The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / November / Adaptive Sampling Advances Pediatric Cancer Profiling
Oncology Omics Precision medicine Research and Innovations Molecular Pathology

Adaptive Sampling Advances Pediatric Cancer Profiling

Rapid nanopore sequencing identifies cancer mutations within hours, offering a potential alternative to multiple diagnostic tests

11/16/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Scorecard
  • Quiz
  • Poll

Share

Objective:

Evaluate whether nanopore whole-genome sequencing with adaptive sampling (AS-WGS) can detect clinically relevant genomic alterations and support tumor classification in pediatric cancers.

Approach:
  • Study samples: Researchers analyzed 36 samples from 35 pediatric patients, including 31 tumor samples from patients with leukemia and solid cancers.
  • Sequencing and analysis: Nanopore whole-genome sequencing with adaptive sampling (AS-WGS) targeted approximately 380 clinically relevant genomic regions while retaining genome-wide information. The team developed the open-source nf-core-oncoseq pipeline to analyze data during sequencing.
  • Comparison: The researchers compared AS-WGS results with conventional diagnostic testing and used DNA methylation information for tumor classification.
Key Findings:
  • Compared with conventional diagnostic testing, AS-WGS detected all 20 previously identified gene fusions, mutations in 58 of 59 affected genes, and 20 of 21 large copy-number alterations.
  • The assay detected mutations present in as little as 5% of sequenced DNA.
  • Within 24 hours, all 20 gene fusions and all 47 evaluated mutations with variant allele frequencies above 25% had at least five supporting reads. Large chromosomal alterations could be identified within the first hour.
  • Methylation-based analysis correctly classified 9 of 11 acute lymphoblastic leukemia samples and 8 of 12 solid tumors.
  • Researchers estimated sequencing costs at approximately CAD $1,700 per sample, compared with more than CAD $5,000 for combined conventional approaches.
Interpretation:

The study authors reported that AS-WGS provided early findings on clinically relevant alterations and combined detection of major genomic alteration classes with methylation-based tumor classification in one workflow.

Limitations:
  • Some variants required manual review, and low-frequency mutation detection could require 72 hours of sequencing.
  • DNA quality and sequencing performance affected results.
  • Further clinical validation is needed to determine whether AS-WGS can replace existing diagnostic workflows and improve treatment decisions.
Conclusion:

In this pediatric cancer sample set, AS-WGS detected many clinically relevant genomic alterations, with some findings available within hours, and supported methylation-based tumor classification.

Sources:
  • Article context; source URL not provided

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Your Privacy Choices
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.